A detailed history of Nwam LLC transactions in Anavex Life Sciences Corp. stock. As of the latest transaction made, Nwam LLC holds 836,730 shares of AVXL stock, worth $3.45 Million. This represents 0.35% of its overall portfolio holdings.

Number of Shares
836,730
Previous 798,293 4.81%
Holding current value
$3.45 Million
Previous $7.43 Million 42.71%
% of portfolio
0.35%
Previous 0.6%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 09, 2024

BUY
$4.55 - $6.75 $174,888 - $259,449
38,437 Added 4.81%
836,730 $4.26 Million
Q4 2023

Feb 14, 2024

BUY
$5.04 - $9.95 $389,607 - $769,164
77,303 Added 10.72%
798,293 $7.43 Million
Q3 2023

Oct 31, 2023

BUY
$6.55 - $9.37 $565,854 - $809,474
86,390 Added 13.61%
720,990 $4.72 Million
Q2 2023

Aug 09, 2023

BUY
$7.66 - $9.5 $661,540 - $820,448
86,363 Added 15.75%
634,600 $5.16 Million
Q1 2023

May 12, 2023

BUY
$8.32 - $11.75 $4.56 Million - $6.44 Million
548,237 New
548,237 $4.7 Million

Others Institutions Holding AVXL

About ANAVEX LIFE SCIENCES CORP.


  • Ticker AVXL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 77,942,800
  • Market Cap $321M
  • Description
  • Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system (CNS) diseases. Its lead drug candidate is ANAVEX 2-73, which is in Phase III clinical trial for the treatment of Alzheimer's disease; Phase III clinical trial to treat pediatric patien...
More about AVXL
Track This Portfolio

Track Nwam LLC Portfolio

Follow Nwam LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Nwam LLC, based on Form 13F filings with the SEC.

News

Stay updated on Nwam LLC with notifications on news.